In India, China and several other nations, Novo Nordisk is on the verge of losing patent protection for its blockbuster weight loss drug, opening the door for cheaper competing versions. By Rebecca ...

Come March 20, when the patent for Semaglutide expires, the Indian market is expected to see the launch of generic drugs from at least seven pharma companies, at costs ranging from one-third to ...

In the ongoing litigation over Apotex's generic version of GlaxoSmithKline's (GSK) antidepressant paroxetine hydrochloride (Paxil), the US Federal Circuit Appeals Court has reversed the previous ...

With patents expiring today in India for Novo Nordisk’s popular diabetes and obesity drugs Ozempic and Wegovy, more than 40 generic drug makers are expected to begin launching their cheaper versions ...

India's pharma industry is ready to flex its generics muscle as the patent for a key ingredient of blockbuster weight-loss drugs expires today. Pharmarack estimates India’s weight-loss drug market to ...

Novo lost semaglutide patent protection in India, triggering generic launches. Indian drugmakers launched generic versions at lower prices. Novo cut prices and used partnerships to defend market share ...

India’s weight-loss drug market is on the verge of a price shake-up. In days, domestic drugmakers are set to launch cheaper versions of semaglutide, the GLP-1 (glucagon-like peptide-1) therapy popular ...

Kantipuly is a preventive medicine and public health resident at McGill University and visiting scholar at the University of New Mexico. Singer is VK Rajah visiting professor of medical ethics at the ...

Following its FDA approval in the summer, Tonix Pharma's fibromyalgia therapy Tonmya has been launched onto the market in the US, becoming the first new drug for the painful condition in more than 16 ...

Some three weeks into the U.S. and Israel’s war with Iran, the expanding conflict’s impact on energy prices and shipping in the region has become impossible to ignore. While much of the immediate ...

Did our AI summary help? At least a dozen large Indian drugmakers are set to roll out copies of Novo Nordisk A/S’s blockbuster weight-loss drugs as soon as the patent expires Friday, crashing prices ...